Greenwich LifeSciences (GLSI) Earnings Date & Reports
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
GLSI is expected to report earnings to fall 8.00% to -23 cents per share on August 14
Q2'23
Est.
$-0.23
Q1'25
Missed
by $0.04
Q4'24
Missed
by $0.40
Q2'24
Est.
$-0.20
Q1'24
Beat
by $0.01
The last earnings report on May 30 showed earnings per share of -25 cents, missing the estimate of -20 cents. With 18.25K shares outstanding, the current market capitalization sits at 131.68M.